The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Analyzing two decades of trends in FDA approvals for GI cancer treatments
Fares Jamal, MD, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, provides insight into the evolving trends of FDA approvals for GI cancer treatments from 2006 to 2024. Findings showed a significant increase in approvals in the later period (2015-2024) and a rise in accelerated approvals and Phase II, single-arm studies. Overall survival remained the most common endpoint, but objective response rate was used more frequently during the later period. Using the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS), substantial clinical benefit was shown to increase over time. Dr Jamal highlights the need to balance efficacy, toxicity, and financial burden while optimizing approval pathways to improve patient outcomes and treatment accessibility. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
